Which AI Sleep Coach Startups Are Worth Investing In?

The AI sleep coach startups with the most verifiable investment cases today are Big Health (FDA-cleared SleepioRx, $23.7 million raised in February 2026), Eight Sleep ($50 million at a $1.5 billion valuation in March 2026), Stellar Sleep ($6 million seed), Sleep Reset, SOND ($7 million), Naptick, Rest and Sleep.ai ($5.5 million), but every one of them is a private company, so most readers cannot simply buy shares. In the US, a private round is normally sold under SEC Regulation D to accredited investors, and none of these eight had an open equity crowdfunding offer that we could find. What some of them do have open is a product pre-order. SOND is taking $449 refundable pre-orders for its Dreambuds and Naptick is selling its $349 bedside device in numbered batches. A pre-order buys you a gadget. It does not buy you equity.

So this article does two jobs. It explains how to judge a sleep coaching company the way a diligence analyst would (clinical evidence, regulatory pathway, retention, unit economics), and it sets out which startups fit the category and what is publicly known about each. Where a number could not be traced to a primary source, we say so.

Key takeaways

• Sleep coaching splits into two regulatory lanes. Big Health's SleepioRx went through FDA 510(k) clearance (K233577, decided 5 August 2024). Naptick, SOND and Rest sell as general wellness products and make no treatment claims.
• The largest disclosed round is Eight Sleep's $50 million at $1.5 billion. The smallest disclosed rounds are $5.5 million to $7 million seeds. Naptick, Rest and Sleep Reset publish no current funding figures.
• FDA clearance is not a business model. Pear Therapeutics won clearance for the insomnia therapeutic Somryst in 2020 and sold it out of bankruptcy for $3.9 million in 2023.
• No company in this article publishes subscriber retention or churn. That is the number that decides whether a coaching product is a business, and you will only see it inside a data room.
• Accredited investor status means income above $200,000 ($300,000 with a spouse) or net worth above $1 million excluding your home, per Investor.gov. Without it, Regulation Crowdfunding is the main legal route into startups, with annual limits.

The eight companies at a glance

We ordered these by how much an outside investor can actually verify, not by product quality. A company near the bottom may make a product you love.

Company	What the coach is	Regulatory lane	Latest disclosed funding	Can the public invest?
Big Health	Sleepio and SleepioRx, automated digital CBT-I	SleepioRx FDA-cleared, prescription only	$23.7M strategic round, Feb 2026	No. Private, institutional round
Eight Sleep	Pod 6 mattress cover with Autopilot AI guidance	Wellness today, FDA filing in progress for sleep apnea	$50M at $1.5B, Mar 2026	No. Private
Stellar Sleep	CBT-I app plus insurance-covered insomnia specialists	Clinician-delivered care plus app	$6M seed, Feb 2024	No. Private
Sleep Reset	Digital sleep clinic with human coaches and a CBT-I based program	Telehealth clinic	Not confirmed from a primary source	No. Private
SOND	Dreambuds in-ear system with a voice AI coach	Wellness	$7M, May 2026	No equity offer found. Product pre-order only
Naptick	Bedside device with "Nap", a conversational AI coach	Wellness	None disclosed	No equity offer found. Product pre-order only
Rest (Evolve)	CBT-I based app with "Rest AI"	Wellness	None disclosed	No. Private
Sleep.ai	Sleep data API and SleepScore app for other brands	Mostly B2B infrastructure	$5.5M, Aug 2025	No. Private

What counts as an AI sleep coach

A sleep coach changes behaviour. A tracker reports on it. That distinction matters for investors because the two have different economics: a tracker sells hardware and maybe a data subscription, while a coach has to keep someone engaged for weeks, which is harder and, when it works, stickier. Our explainer on what a sleep coach is covers the consumer side of this.

The clinical gold standard for coaching is cognitive behavioural therapy for insomnia, or CBT-I. The US National Heart, Lung, and Blood Institute describes it as a 6 to 8 week plan that is usually recommended as the first treatment option for long-term insomnia, and notes it can be delivered in person, by phone or online. The online version has real trial evidence behind it. A PLOS ONE meta-analysis of 15 randomized trials found internet-delivered CBT-I improved sleep efficiency by 7.2 percentage points and cut Insomnia Severity Index scores by 4.3 points against control.

That evidence belongs to CBT-I as a method. It does not transfer automatically to any product that borrows the vocabulary. A conversational AI that talks you through a restless night may help, but nobody has published a trial showing that a chatbot wind-down equals a structured CBT-I programme. When a pitch deck says "evidence-based", ask which product was in the trial.

How we evaluated these companies

We read each company's own website on 13 October 2026, then checked funding claims against the original press coverage or release. Four questions shaped the ordering.

First, evidence. Has the specific product been tested in a peer-reviewed trial, or is the company pointing at the general CBT-I literature? Testimonials on a product page were given no weight.

Second, regulatory pathway. FDA's general wellness policy, reissued in January 2026, lets low-risk products that promote a healthy lifestyle reach the market without premarket review, provided they stay away from disease claims. The alternative is clearance as a "computerized behavioral therapy device for insomnia", the classification both SleepioRx and Somryst carry in FDA's 510(k) database. The first is quick and cheap but blocks any claim to treat insomnia. The second allows prescription and reimbursement, but takes time and money.

Third, retention. A coaching product earns its keep only if people keep using it. We looked for published retention, renewal or churn data and found none for any of the eight.

Fourth, unit economics. We recorded what each company charges, whether revenue recurs, and whether the price is on its own site today. We did not estimate margins, because no company here publishes cost of goods and the margin ranges that circulate for sleep hardware and software had no source we could find.

One thing we could not do: search SEC Form D filings for each company. EDGAR blocked our automated requests, so "none disclosed" in this article means none found in press coverage or on the company's site, not a confirmed absence of filings.

Can you actually invest in these startups?

For most people, no, at least not directly. Here are the real routes.

Regulation D and the accredited investor test

Venture rounds like Eight Sleep's are private placements. Under Rule 506 of Regulation D, a company can raise an unlimited amount from accredited investors without registering the offering. Rule 506(b) also permits up to 35 non-accredited but financially sophisticated purchasers, though startups rarely use that allowance. Under 506(c) the company may advertise the round publicly, but every buyer must be accredited and the company has to take reasonable steps to verify it.

The SEC's investor education site sets out the individual tests: earned income above $200,000 (or $300,000 with a spouse or spousal equivalent) in each of the prior two years with the same expected this year, or net worth above $1 million excluding your primary residence, or a Series 7, 65 or 82 licence in good standing. Meeting the test does not get you an allocation. A $50 million strategic round led by a single investor is not open to walk-ins. And what you buy is restricted stock, which Investor.gov notes cannot be resold for at least six months or a year without registration.

Regulation Crowdfunding

Regulation Crowdfunding is the route built for everyone else. A company can raise up to $5 million in 12 months from the general public, but only through an SEC-registered broker-dealer or funding portal. Investor.gov's bulletin gives the limits for non-accredited investors. If your income or net worth is under $124,000, you can put in the greater of $2,500 or 5% of the larger figure across all such offerings in a year. If both are at or above $124,000, the cap is 10% of the larger figure, up to $124,000. Resale is restricted for the first year, and the bulletin is blunt that these investments are speculative and that early-stage ventures often fail.

We found no live Regulation Crowdfunding offering from any of the eight companies. TechCrunch reported in May that SOND planned "a crowdfunding campaign" ahead of mass production. That phrase usually means rewards crowdfunding, where backers receive a product. Whether SOND meant that or an equity raise is not something we could confirm.

Pre-orders are not investments

This is the confusion worth clearing up. A line like "Batch 3 is open" on a startup's site can read like a funding round. It is not one. On Naptick's product page, a batch is a production run of devices: Batches 1 and 2 are marked sold out and Batch 3 is listed as open at $349. SOND's page works the same way, with a $449 pre-order price against a $650 list price and a deposit it describes as fully refundable.

Buying either gives you consumer rights (Naptick advertises a 60-night money-back guarantee and a one-year warranty) and no ownership. If the company later raises at a high valuation, a pre-order customer gains nothing from it.

Public comparables

If you want sleep exposure through a brokerage account, the listed options are device makers, not coaching startups. Our earlier piece on companies to invest in for smart sleep covers the two public names, ResMed and Sleep Number, alongside the larger private device makers. Neither is a pure coaching business, and a position in either is a bet on CPAP demand or mattress sales, with coaching as a minor feature at most.

The regulated end: digital CBT-I

Big Health (Sleepio and SleepioRx)

Big Health is the clearest example of coaching software that took the medical route. FDA's database shows the 510(k) for Sleepio was received on 7 November 2023 and cleared on 5 August 2024, about nine months. In February 2026 the company announced a $23.7 million strategic round co-led by .406 Ventures and AlleyCorp, with CVS Health Ventures participating.

The investment case rests on reimbursement. Big Health says SleepioRx and its anxiety product DaylightRx are among nine FDA-cleared treatments in a Medicare category for digital mental health treatments created in the 2025 Physician Fee Schedule. We could not load the CMS pages to confirm the count independently, so treat it as the company's statement. Big Health also claims more than 750,000 people supported and that up to 76% of SleepioRx patients improve, both self-reported figures tied to its own cited studies.

What to weigh against that: SleepioRx is available only by order of a licensed provider, so growth depends on clinicians prescribing software, which has historically been slow. The consumer version of Sleepio, by the company's own footer, has not been reviewed by FDA. And "strategic funding" with no stated valuation tells an outsider little about how earlier investors fared.

The Pear Therapeutics warning

Anyone tempted to treat FDA clearance as a moat should read the Somryst history. Pear Therapeutics received 510(k) clearance for Somryst on 23 March 2020, at the time the only FDA-authorized prescription digital therapeutic for chronic insomnia. Three years later Pear filed for Chapter 11, and Nox Health bought the Somryst assets at auction for $3.9 million. The product worked well enough to clear FDA. Payers did not cover it widely enough to support the company. The Medicare codes that arrived in 2025 change that picture somewhat, but they came too late for Pear's shareholders.

Stellar Sleep

Stellar Sleep sits between software and clinic. It began as a CBT-I app, went through Y Combinator's Summer 2023 batch, and announced a $6 million seed led by Initialized Capital in February 2024. Its site now offers either the app programme or a matched insomnia specialist covered by insurance, and promotes an internal AI system called Rhythm that handles administrative work for its clinicians.

The founders said in their YC launch post that the app reached $1 million in annual run rate within nine months of launch. That is a founder's claim from 2023 and we have nothing more recent. Y Combinator's directory lists a team of five. The shift toward insurance-billed clinicians suggests the app-only model was not enough, which is useful information about the whole category.

Sleep Reset

Sleep Reset calls itself a digital sleep clinic. It pairs a CBT-I based programme with human coaches, and its clinicians also diagnose and treat obstructive sleep apnea through home testing. It is one of the few companies here with public pricing: a $19 one-week trial, then $297 per 28 days, and it says it accepts more than a hundred insurance plans.

It came through Y Combinator in Winter 2017, and the YC directory lists eight employees. We could not confirm any funding round from a primary source. Data aggregators disagree on both the total and the dates, so we are not quoting them. At $297 a month the revenue per customer is high, but a programme designed to fix insomnia in a few months has churn built in. A customer who gets better leaves.

The consumer end: devices with a coach inside

Eight Sleep

Eight Sleep is the only company in this group with a disclosed valuation. TechCrunch reported on 4 March 2026 that it raised $50 million in a strategic round led by Tether Investments at $1.5 billion, after a $100 million round in August 2025. The March round is sometimes labelled a Series C. It was not one. The Series C was an $86 million round in 2021 at a $500 million post-money valuation.

The coaching element is Autopilot, software that adjusts bed temperature through the night, plus AI guidance that the company says has changed habits like caffeine timing in early pilots. The hardware is the Pod 6, from $1,999 for solo sizes and $2,699 for standard sizes, with a membership on top.

The company told TechCrunch it was free-cash-flow positive in 2025. It has never disclosed revenue. It is also trying to cross regulatory lanes: Fortune reported in August that Eight Sleep is pursuing FDA clearance for sleep apnea detection and mitigation and that the filing is in progress. Not cleared. The same article notes only one independent study of the Pod has been published. There is operational risk too. An AWS outage in October 2025 left Pods unable to reach the company's servers and some beds overheated, which pushed the company to add an offline mode.

SOND

SOND fits the "AI sleep coach" label more literally than anyone else here. Its Dreambuds capture 12 physiological signals in the ear and respond with audio, and the wearer can double-tap and talk to a voice coach. TechCrunch covered its launch on 27 May 2026 with $7 million from E14 Fund, Crosslink Capital, Ubiquity Ventures and others. Chief executive Yadid Ayzenberg previously ran sleep products at Bose.

The product has not shipped. SOND's site says it is in pre-production with estimated delivery in December 2026. For an investor that means zero retention data, no reviews from paying customers, and a hardware schedule that has yet to be tested. Bose itself left this market, which cuts both ways: it left a gap, and it suggests a large audio company could not make sleep earbuds pay.

Naptick

Naptick sells a $349 bedside device that combines a conversational AI coach called Nap, a library of more than 1,000 soundscapes, warm light for wind-down and wake-up, and room sensors for CO2, VOCs, particulates, temperature, humidity, light and noise that roll up into a 0 to 100 room score. It syncs with Oura, Whoop, Apple Watch and Garmin. There is no subscription, and the companion app is free with the device.

For an investor, the public record is thin. Naptick's site discloses no funding round, no investors and no valuation, and we found no press coverage of a raise. The team page lists three co-founders, with chief executive Anubhab Goel described as a two-time founder with more than $200 million in combined exits. The company states plainly that the product is a wellness device and is not intended to diagnose or treat any condition.

What to consider:

• No peer-reviewed study of the device or its coach is cited on the site. The science page explains the reasoning behind light, sound and air quality, and the customer quotes are testimonials.
• A one-time $349 sale with a free app means no recurring revenue as currently priced. That is good for buyers and a question for investors, since each customer is paid for once.
• The app is iOS only. Android is listed as coming soon.
• Shipping status is unclear. As of 13 October 2026 the product page still said Batch 3 "ships August 2026".
• It depends on third-party wearables for sleep-stage data.

Naptick is at a similar stage to SOND, a wellness-lane hardware startup selling in pre-order batches. Unlike SOND, it has no disclosed institutional backing to benchmark against.

Rest

Rest is an app built on CBT-I principles with a chat coach called Rest AI, made by Evolve, a Y Combinator Winter 2018 company. Its site says the self-guided programme is free with no subscription and describes the product as a self-management and wellbeing tool, not a treatment. No funding is disclosed for Rest specifically.

A free core product with clinical-sounding content is a reasonable way to acquire users. Whether it converts to revenue is unknown from the outside.

Sleep.ai

Sleep.ai, formerly SleepScore Labs, raised $5.5 million led by Treasure Coast Ventures in August 2025. It is less a coach than a supplier to coaches: its main offer is a sleep API and research service for other brands, alongside the SleepScore consumer app. The company says it holds more than 800 million hours of sleep data and has run over 250 studies. Those are its own figures. A decade-old company raising a $5.5 million round is a restart, and should be valued as one.

Companies and numbers we left out

Two Y Combinator companies that turn up in lists of sleep coaching startups do not belong in this category. Equipt Health handles logistics for prescription medical devices. Zeit Medical works on stroke detection and does not appear in YC's sleep tech directory, which lists four companies today, not five. The actual YC sleep coaching companies are Sleep Reset, Rest and Chorus Sleep, a four-person team selling a coaching programme to employers.

We also removed a set of figures that had no traceable source: hardware and software gross margin ranges, "typical" seed sizes, retention benchmarks, exit multiples by category and market size forecasts. Some may be roughly right. None could be tied to data we could read.

Diligence checklist for a sleep coaching pitch

Question	Good answer	Warning sign
What evidence exists for this product?	A registered, peer-reviewed trial of the product itself	Citations to general CBT-I research, or testimonials
Which regulatory lane?	A clear choice, with claims that match it	Wellness product using treatment language
Who pays?	Named payers, employers or a price consumers already pay	"Reimbursement is coming"
What is 90-day retention?	A cohort chart, shared before you ask twice	Download counts or total registered users
Does revenue recur?	Subscription or per-episode billing with renewal data	One-time hardware sale with a free app and no stated plan
Has the hardware shipped?	Units in customers' hands, return rate known	Pre-orders only, delivery date already moved
What happens if the cloud goes down?	Device works offline	Core function depends on a server

Limitations

We did not speak to any of these companies, and none reviewed this article. Funding figures come from press coverage and company releases, and private valuations in particular are whatever the company and its lead investor chose to announce. We could not search SEC EDGAR for Form D filings, so undisclosed rounds may exist, including for Naptick, Rest and Sleep Reset. We could not load CMS pages to verify the Medicare digital mental health treatment codes directly and relied on Big Health's description of them. Sleep Reset's funding history is unverified. No company's retention, revenue or margin data is public, which means the ordering in this article reflects disclosure, not business quality. Product claims about sleep improvement are the companies' own unless we cite a trial. Nothing here is a recommendation to buy any security, and nothing here is medical advice. If you have persistent insomnia, speak to a clinician.

Frequently asked questions

Can a retail investor buy shares in an AI sleep coach startup?

Generally not. All eight companies covered here are private. Their rounds are sold to institutions and accredited investors under Regulation D, and we found no open Regulation Crowdfunding offering from any of them. If one launches, it must run through an SEC-registered funding portal or broker-dealer, and non-accredited investors face the annual limits described above.

Is pre-ordering a Naptick or SOND device a way to invest in the company?

No. A pre-order is a purchase. Naptick's "batches" are production runs of its $349 device, and SOND's $449 pre-order is a refundable deposit on earbuds expected in December 2026. Neither gives you equity or any share in the company's future value.

Which AI sleep coach startup has raised the most?

Eight Sleep, by a wide margin. TechCrunch, citing Crunchbase, puts its total above $310 million, with the latest $50 million at a $1.5 billion valuation in March 2026. Among companies whose main product is coaching software, Big Health's $23.7 million round in February 2026 is the largest recent one we could verify.

Does FDA clearance make a sleep coaching company a safer investment?

It makes the product's claims more credible. It says little about the business. SleepioRx and Somryst hold the same FDA classification. Big Health raised new money in 2026, while Somryst's original owner, Pear Therapeutics, went bankrupt in 2023. The difference lies in who pays and how fast clinicians prescribe.

What is the difference between a wellness sleep coach and a digital therapeutic?

A wellness product can encourage healthy sleep habits but cannot claim to treat insomnia or any other condition, and under FDA's general wellness policy it does not need premarket review. A digital therapeutic such as SleepioRx is a medical device, cleared by FDA for a stated condition and available by prescription. Naptick, SOND and Rest all describe themselves as wellness products.

What should I ask before investing in a sleep coaching startup?

Ask for 90-day retention by cohort, the trial evidence for the specific product, the regulatory plan and what it will cost, and who pays today. Then ask what happens to revenue when a customer's sleep improves, because a coach that works can lose its customers by succeeding.

Conclusion

Sleep coaching is a real category with real clinical evidence behind its best method, and almost none of it is open to ordinary investors. The companies with the most to show an outsider are Big Health on the regulated side and Eight Sleep on the consumer side. SOND and Naptick are earlier, with products still in pre-order and little or nothing disclosed about traction. If you are accredited and see a deal, the checklist above is where to start. If you are not, the honest position is that you can buy these products, follow these companies, and wait for either a registered crowdfunding offer or a public listing. Neither exists today.

---

This article is for general informational purposes only and is not investment, financial, or legal advice, nor a recommendation to buy, sell, or hold any security or to invest in any company. Sleep-tech valuations, funding rounds, and company details change quickly and may be out of date; do your own diligence and consult a licensed financial professional before making any investment decision.

Reviewed for accuracy by the Sleep Routine Guide editorial team. Company, funding and product details were cross-referenced against the cited sources as of the review date. Last reviewed: October 13, 2026.